<DOC>
	<DOCNO>NCT02206659</DOCNO>
	<brief_summary>To assess trough/peak ratio 40 mg Telmisartan tablet ambulatory blood pressure monitor Chinese patient mild moderate essential hypertension</brief_summary>
	<brief_title>Effects Telmisartan Ambulatory Blood Pressure Monitoring ( ABPM ) Chinese Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Chinese male female age 18 75 year Mild moderate hypertension define morning DBP _95 &lt; 110 mm Hg visit1 visit 2 . Mean sit systolic pressure ( SBP ) must &lt; 180 mm Hg Ability provide write informed consent Women pregnant breastfeeding , childbearing potential without effective method birth control ( effective birth control method : uterine device , surgical sterilisation , progestogens alone ) Known suspect secondary hypertension Known history chronic hepatic disease Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant New York Heart Association ( NYHA ) functional class congestive heart failure ( CHF ) IIIIV Unstable angina pectoris Myocardial infarction percutaneous transluminal coronary angiography ( PTCA ) cardiac surgery within precede three month Clinical relevant cardiac arrhythmia determine clinical investigator Hypertrophic obstructive cardiomyopathy clinically significant valvular disease Evidence retinal hemorrhages/exudates Clinical significant hyperkalemia define serum potassium level &gt; 6.0 milliequivalent ( mEq ) /L Insulindependent diabetes mellitus Noninsulindependent diabetes mellitus poor glucose control define persistent fasting blood sugar &gt; 200 mg/dl , peripheral neuropathy autonomic neuropathy Known drug alcohol dependency Administration diuretic , ACE inhibitor angiotensin II receptor antagonist within two week runin period Administration medication know affect blood pressure trial period Patients receive investigational therapy within one month signing informed consent form Known hypersensitivity component formulation Any clinical condition , opinion principal investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>